EYPT
Price
$14.79
Change
+$0.05 (+0.34%)
Updated
Nov 26 closing price
Capitalization
1.22B
98 days until earnings call
Intraday BUY SELL Signals
ORMP
Price
$2.85
Change
-$0.03 (-1.04%)
Updated
Nov 26 closing price
Capitalization
114.63M
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EYPT vs ORMP

Header iconEYPT vs ORMP Comparison
Open Charts EYPT vs ORMPBanner chart's image
EyePoint Pharmaceuticals
Price$14.79
Change+$0.05 (+0.34%)
Volume$850.34K
Capitalization1.22B
Oramed Pharmaceuticals
Price$2.85
Change-$0.03 (-1.04%)
Volume$272.21K
Capitalization114.63M
EYPT vs ORMP Comparison Chart in %
EYPT
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
EYPT vs. ORMP commentary
Nov 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Hold and ORMP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 28, 2025
Stock price -- (EYPT: $14.79 vs. ORMP: $2.88)
Brand notoriety: EYPT and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 63% vs. ORMP: 151%
Market capitalization -- EYPT: $1.22B vs. ORMP: $114.63M
EYPT [@Biotechnology] is valued at $1.22B. ORMP’s [@Biotechnology] market capitalization is $114.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $109.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, both EYPT and ORMP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 5 bullish TA indicator(s).

  • EYPT’s TA Score: 5 bullish, 5 bearish.
  • ORMP’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both EYPT and ORMP are a good buy in the short-term.

Price Growth

EYPT (@Biotechnology) experienced а +3.57% price change this week, while ORMP (@Biotechnology) price change was +15.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -1.24%, and the average quarterly price growth was +71.95%.

Reported Earning Dates

EYPT is expected to report earnings on Mar 05, 2026.

ORMP is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($1.22B) has a higher market cap than ORMP($115M). EYPT YTD gains are higher at: 98.523 vs. ORMP (17.769). ORMP has higher annual earnings (EBITDA): -22.07M vs. EYPT (-172.05M). EYPT has more cash in the bank: 256M vs. ORMP (97.9M). ORMP has less debt than EYPT: ORMP (912K) vs EYPT (21.8M). EYPT has higher revenues than ORMP: EYPT (51.9M) vs ORMP (2M).
EYPTORMPEYPT / ORMP
Capitalization1.22B115M1,064%
EBITDA-172.05M-22.07M779%
Gain YTD98.52317.769554%
P/E RatioN/A2.88-
Revenue51.9M2M2,595%
Total Cash256M97.9M261%
Total Debt21.8M912K2,390%
FUNDAMENTALS RATINGS
EYPT vs ORMP: Fundamental Ratings
EYPT
ORMP
OUTLOOK RATING
1..100
2326
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
7098
SMR RATING
1..100
9691
PRICE GROWTH RATING
1..100
3739
P/E GROWTH RATING
1..100
14100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (39) in the Pharmaceuticals Other industry is in the same range as EYPT (71) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (70) in the Pharmaceuticals Major industry is in the same range as ORMP (98) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as EYPT (96) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as ORMP (39) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew similarly to ORMP’s over the last 12 months.

EYPT's P/E Growth Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew significantly faster than ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTORMP
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 23 days ago
87%
Bearish Trend 14 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
EYPT
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MNDKX35.200.14
+0.40%
MFS New Discovery R6
TSWEX14.68N/A
N/A
TSW Large Cap Value Institutional
NRILX15.15N/A
N/A
Neuberger Berman International Sel R6
GWGZX20.06N/A
N/A
AMG GW&K Small Mid Cap Core Z
FECMX48.39N/A
N/A
Fidelity Advisor Emerging Markets I

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+0.34%
OCUL - EYPT
60%
Loosely correlated
+0.08%
LYRA - EYPT
58%
Loosely correlated
+22.92%
ATHE - EYPT
54%
Loosely correlated
+7.72%
IDYA - EYPT
49%
Loosely correlated
+1.13%
BEAM - EYPT
48%
Loosely correlated
+1.38%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-1.04%
BTAI - ORMP
44%
Loosely correlated
+8.90%
INO - ORMP
44%
Loosely correlated
+8.29%
MBIO - ORMP
44%
Loosely correlated
+5.08%
ZNTL - ORMP
43%
Loosely correlated
N/A
RVMD - ORMP
42%
Loosely correlated
+1.65%
More